• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[胸苷激酶在预测乳腺癌化疗或激素治疗反应中的价值]

[Value of thymidine kinase in the prediction of response to treatment by chemotherapy or hormone therapy in breast cancer].

作者信息

Bennini N, Mauriac L, Wafflart J, Bonichon F, Durand M

机构信息

Fondation Bergonié, Bordeaux, France.

出版信息

Bull Cancer. 1992;79(8):773-9.

PMID:1467600
Abstract

Thymidine kinase (TK) was assayed in the cytosol of 210 primary breast cancers to assess its predictive value for response to first line chemotherapy and hormonotherapy. We performed correlations between TK and the other prognosis factors of breast cancer. TK activity is correlated with SBR grading and estrogen receptors. It has a low predictive value for response to chemotherapy and is not useful for hormonotherapy.

摘要

对210例原发性乳腺癌的细胞溶质进行胸苷激酶（TK）检测，以评估其对一线化疗和激素治疗反应的预测价值。我们对TK与乳腺癌的其他预后因素进行了相关性分析。TK活性与肿瘤组织学分级（SBR）和雌激素受体相关。它对化疗反应的预测价值较低，对激素治疗也无用处。

相似文献

1
[Value of thymidine kinase in the prediction of response to treatment by chemotherapy or hormone therapy in breast cancer].[胸苷激酶在预测乳腺癌化疗或激素治疗反应中的价值]
Bull Cancer. 1992;79(8):773-9.
2
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.晚期乳腺癌中的胸苷激酶和胸苷酸合成酶：对他莫昔芬和化疗的反应
Cancer Res. 2001 Feb 15;61(4):1421-5.
3
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.血管内皮生长因子和胸苷磷酸化酶在接受辅助化疗或激素治疗的淋巴结阳性乳腺癌患者中的临床相关性。
Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11.
4
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.微管相关蛋白tau是雌激素受体阳性乳腺癌内分泌敏感性和化疗耐药性的双功能预测指标。
Clin Cancer Res. 2007 Apr 1;13(7):2061-7. doi: 10.1158/1078-0432.CCR-06-2078.
5
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.血管内皮生长因子在肿瘤中的高表达预示晚期乳腺癌患者对全身治疗反应较差。
Cancer Res. 2001 Jul 15;61(14):5407-14.
6
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.bcl-2蛋白的表达可预测可手术的淋巴结阳性乳腺癌辅助治疗的疗效。
Clin Cancer Res. 1995 Feb;1(2):189-98.
7
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.TP53基因的全序列分析预示晚期乳腺癌对全身治疗反应不佳。
Cancer Res. 2000 Apr 15;60(8):2155-62.
8
[Prognostic value of thymidine kinase in cancer of the breast].[胸苷激酶在乳腺癌中的预后价值]
Bull Cancer. 1990;77(10):973-83.
9
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.前列腺特异性抗原（PSA）的表达与复发性乳腺癌对他莫昔芬治疗的不良反应相关。
Br J Cancer. 1999 Feb;79(5-6):888-94. doi: 10.1038/sj.bjc.6690142.
10
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.核苷代谢酶对绝经前淋巴结阳性原发性乳腺癌患者的预测意义，这些患者被随机分配接受单纯他莫昔芬或他莫昔芬加替加氟-尿嘧啶作为辅助治疗。
Int J Oncol. 2007 Oct;31(4):899-906.